Anti-dementia drugs and changes in gait: A pre-post quasi-experimental pilot study

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Beauchet, Olivier ^a   Launay, Cyrille P ^a   Allali, Gazan ^b   Watfa, Gilles ^c   Gallouj, Karim ^d   Herrmann, François R ^b   Annweiler, Cédric ^a,e  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d Tourcoing Hospital   (France)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer disease; Anti dementia drugs; Gait; Stride time variability

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

AGED; ALZHEIMER DISEASE; ALZHEIMERS DISEASE RELATED DISORDER; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; DSM-IV; FEMALE; FOLLOW UP; GAIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; QUASI EXPERIMENTAL STUDY; STEADY STATE; VERY ELDERLY; WALKING SPEED;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; GAIT; HUMANS; MALE; MEMANTINE; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84887899674     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-184     Document Type: Article

References (19)

1. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 2009, 9:591-598. 10.1586/ern.09.23, 19402770.
2. Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2007, 2:17-32. 10.2147/ciia.2007.2.1.17, 2684084, 18044073.
3. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs 2009, 23:881-897. 10.2165/11201020-000000000-00000, 19739697.
4. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol 2009, 9:42. 10.1186/1471-2377-9-42, 3224736, 19674471.
5. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc 2009, 57:359-360. 10.1111/j.1532-5415.2009.02085.x, 19207156.
6. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc 2008, 56:946-947. 10.1111/j.1532-5415.2008.01657.x, 18454755.
7. Beauchet O, Allali G, Launay C, Fantino B, Annweiler C. Does memantine improve the gait of individuals with Alzheimer's disease?. J Am Geriatr Soc 2011, 59:2181-2182. 10.1111/j.1532-5415.2011.03648.x, 22098042.
8. Annweiler C, Beauchet O, Bartha R, Wells JL, Borrie MJ, Hachinski V, Montero-Odasso M. Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study. Brain 2013, 136:859-871. 10.1093/brain/aws373, 23436505.
9. Beauchet O, Annweiler C, Montero-Odasso M, Fantino B, Herrmann FR, Allali G. Gait control: a specific subdomain of executive function?. J Neuroeng Rehabil 2012, 9:12. 10.1186/1743-0003-9-12, 3308913, 22321772.
10. Rosano C, Brach J, Longstreth WT, Newman AB. Quantitative measures of gait characteristics indicate prevalence of underlying subclinical structural brain abnormalities in high-functioning older adults. Neuroepidemiology 2006, 26:52-60. 10.1159/000089240, 16254454.
11. Beauchet O, Allali G, Annweiler C, Bridenbaugh S, Assal F, Kressig RW, Herrmann FR. Gait variability among healthy adults: low and high stride-to-stride variability are both a reflection of gait stability. Gerontology 2009, 55:702-706. 10.1159/000235905, 19713694.
12. Almeida QJ, Frank JS, Roy EA, Patla AE, Jog MS. Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease. Mov Disord 2007, 22:1735-1742. 10.1002/mds.21603, 17557356.
13. Ebersbach G, Baas H, Csoti I, Müngersdorf M, Deuschl G. Scales in Parkinson's disease. J Neurol 2006, 253:iv32-iv35. 10.1007/s00415-006-1108-9, 16944355.
14. Shah A, Herbert R, Lewis S, Mahendran R, Platt J, Bhattacharyya B. Screening for depression among acutely ill geriatric inpatients with a short geriatric depression scale. Age Ageing 1997, 26:217-221. 10.1093/ageing/26.3.217, 9223718.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984, 34:939-944. 10.1212/WNL.34.7.939, 6610841.
16. Kressig RW, Beauchet O. Guidelines for clinical applications of spatio-temporal gait analysis in older adults. Aging Clin Exp Res 2006, 18:174-176. 10.1007/BF03327437, 16702791.
17. Stavitsky K, Brickman AM, Scarmeas N, Torgan RL, Tang MX, Albert M, Brandt J, Blacker D, Stern Y. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2006, 63:1450-1456. 10.1001/archneur.63.10.1450, 17030662.
18. Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F. Gait analysis in demented subjects: Interests and perspectives. Neuropsychiatr Dis Treat 2008, 4:155-160. 2515920, 18728766.
19. Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease-input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials 2011, 12:230. 10.1186/1745-6215-12-230, 3212921, 22014101.